SLS:NSD-Sellas Life Sciences Group Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.355

Change

0.00 (0.00)%

Market Cap

USD 0.08B

Volume

1.41M

Analyst Target

USD 8.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+8.09 (+1.70%)

USD 117.92B
REGN Regeneron Pharmaceuticals Inc

+12.58 (+1.27%)

USD 108.54B
MRNA Moderna Inc

+9.50 (+6.54%)

USD 63.85B
BNTX BioNTech SE

+3.02 (+3.04%)

USD 22.68B
ARGX argenx NV ADR

+6.42 (+1.70%)

USD 22.66B
ALNY Alnylam Pharmaceuticals Inc

+2.30 (+1.54%)

USD 18.94B
GMAB Genmab AS

+0.24 (+0.84%)

USD 18.15B
BGNE BeiGene Ltd

+3.94 (+2.54%)

USD 17.32B
RPRX Royalty Pharma Plc

-0.02 (-0.07%)

USD 15.90B
BMRN Biomarin Pharmaceutical Inc

+0.58 (+0.73%)

USD 14.34B

ETFs Containing SLS

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 27.83% 76% C+ 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.83% 76% C+ 86% B+
Trailing 12 Months  
Capital Gain -10.86% 60% D- 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.86% 60% D- 37% F
Trailing 5 Years  
Capital Gain 59.39% 82% B 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.39% 82% B 74% C
Average Annual (5 Year Horizon)  
Capital Gain 340.99% 96% N/A 98% N/A
Dividend Return 340.99% 96% N/A 98% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 1,891.89% 5% F 2% F
Risk Adjusted Return 18.02% 75% C 55% F
Market Capitalization 0.08B 42% F 35% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.